Abstract
Introduction
Heart failure is currently one of the leading causes of hospitalization. Heart failure will become even more of a medical challenge as average life expectancy continues to rise. Despite significant improvements in maximal medical management, approximately 50% of patients with heart failure are dead within 3 years of clinical presentation. While heart transplantation is now considered standard treatment for selected patients with severe heart failure, it is only applicable to a small % of these patients. Transplantation is limited, both by the small number of donor hearts available, and its inapplicability in the older patient or those with comorbid medical conditions that would preclude them from consideration w x for transplantation. 1 In an effort to address this problem, alternative and new surgical strategies have evolved, including coronary artery revascularization U Corresponding author. Tel.: q1-734-936-4981; fax: q1-734-
764-2255.
Ž . E-mail address: sbolling@umich.edu S.F. Bolling . w x w x 2,3 , mechanical circulatory support 4᎐6 , cardiow x w x myoplasty 2,7 , left ventricular myoreduction 8,9 , w x and mitral valve repair 10᎐14 .
Functional mitral regurgitation is a significant complication of end-stage heart failure, and may affect almost all heart-failure patients as a pre-terminal or terminal event. The mitral regurgitation develops secondary to an alteration in the annular-ventricular w x w x apparatus 15 and altered ventricular geometry 16 , which results in incomplete leaflet coaptation. In ischemic heart failure this can be attributed to papillary or lateral wall muscle dysfunction, and in non-ischemic heart failure it can be ascribed to annular dilation w x and chordal tethering 17 , all as a result of dysfunctional remodeling. Mitral regurgitation exacerbates w x the volume overload 18 of the already dilated ventricle, with further progression of annular dilation, increased left ventricular wall tension, worsening mitral regurgitation and increased failure, which predicts a w x poor outcome 19 .
Historically, the surgical approach to patients with functional mitral regurgitation was mitral valve replacement, and little was understood of the adverse ( ) consequences that interruption of the annuluspapillary muscle continuity had on left ventricular w x systolic function 20 . This procedure was associated w x with very high mortality rates 21,22 . It is in this population of patients that the concept of the 'pop-off' effect of mitral regurgitation originated, that is, reversal of blood flow was somehow beneficial to the patient in heart failure. It has been demonstrated in a number of studies that preservation of the annuluspapillary muscle continuity is of paramount importance to preservation of left ventricular function w x 23,24 . It was the excision and disruption of the subvalvular apparatus that accounted for the significant loss of systolic function and led to the poor outcome in the earlier patients who underwent mitral w x valve replacement 25,26 . Preservation of the mitral valve apparatus and left ventricle in mitral valve re-Ž pair in rheumatic and degenerative mitral valve dis-. ease has been demonstrated to enhance and maintain left ventricular function and geometry with an w x associated decrease in wall stress 27,28 . This procedure has been shown to be safe, with a significant decrease in operative morbidity and mortality, and w x good long-term outcomes 29᎐32 .
In order to address the issue of heart failure and mitral regurgitation, the anatomy of the mitral valve must first be understood. The determination of mitral competence depends on an understanding that the mitral valve apparatus consists of the annulus, leaflets, chordae tendinae, papillary muscles, and the entire left ventricle. Maintenance of the chordal, annular and subvalvular continuity and mitral geometric relationships are important in the preservation of overall ventricular function, and may be even more important in those patients with compromised left-ventricular function. When selecting a surgical approach to the problem of heart failure, it must, therefore, first be recognized that this is a ventricular problem, and therefore a solution directed solely at the mitral valve, neglecting the left ventricle, is not ideal. Excision of a portion of the left ventricular wall does not address the issue directly, and in fact can further disrupt the mitral valve apparatus by disruption of the left ventricular wall.
Surgical procedure
At the University of Michigan between June 1993 and January 1999, 92 patients with end-stage heart failure and refractory severe mitral regurgitation were studied prospectively. All patients had NYHA class III or IV heart failure despite receiving maximal Ž medical therapy digoxin, diuretics, and afterload-re-. ducing agents , and had severe left ventricular systolic dysfunction as defined by an ejection fraction -25% on angiography or radionuclide studies. Patient ages Ž . ranged from 33 to 81 years mean 60 " 5 years . Patients were equally divided between non-ischemic dilated heart failure and end-stage ischemic heart failure without ongoing ischemia, as defined by a negative dobutamine echocardiogram andror a negative positron emission tomography scan, and therefore would not be expected to gain any improvement from a coronary artery revascularization procedure. The mean duration of documented heart failure was Ž . 3 " 6 years range 0᎐16 . Pre-operative ejection frac-Ž . tion ranged from 8 to 24% mean 14% . At surgery, all patients underwent mitral valve reconstruction with implantation of an undersized flexible annuloplasty, remodeling ring; no patients underwent a complex mitral valve repair. Additional procedures included, 38 DeVega tricuspid annuloplasties, seven single coronary artery bypass grafts in patients with coronary artery disease discovered as an incidental finding, and implantation of one ICD patch. Mitral valve reconstruction was performed via median sternotomy with cardiopulmonary bypass, utilizing hypothermic, blood cardioplegic arrest in patients undergoing a first operation, and via right thoracotomy, utilizing cold fibrillatory arrest in 38 redo patients who had undergone prior coronary artery bypass grafting.
Results
Intra-operative transesophageal echocardiography revealed no mitral regurgitation in most patients, and mild regurgitation in seven at the end of the procedure. All patients were weaned from cardiopulmonary bypass and maintained in the immediate post-operative period on milrinone and norepinephrine infusions.
There was one intra-operative mortality from right ventricular failure, in a patient who died despite both Ž . the use of the intra-aortic balloon pump IABP and mechanical right ventricular assist device support. Five patients required IABP support, but none required the use of a left ventricular assist device.
In the postoperative period in our study, seven patients required longer than 24 h of mechanical ventilator support, and only three patients for longer than 48 h. There was one late wound infection. There were no other in-hospital deaths and the mean length Ž . of stay following the procedure was 9 " 4 range 4᎐37 Ž days. There were five 30-day mortalities overall oper-. ative mortality was 5% , one due to cardiac failure, one due to a stroke, two due to multisystem organ failure, primarily related to underlying pulmonary failure, and the one intra-operative death mentioned previously. 
Ž
We followed these patients for 1᎐68 months mean . 38 , with a 1-and 2-year actuarial survival of 80 and 70%, respectively. All patients remained on medical therapy for their heart failure. Patients did not undergo routine placement of ICD devices, nor were they placed on amiodarone therapy unless clinically indicated. On immediate post-operative echocardiograms, the mean trans-mitral diastolic gradient was Ž . 3 " 1 mm Hg range 2᎐6 , there were no cases of Ž . mitral stenosis or systolic anterior motion SAM . At 24-month follow-up all remaining patients, without loss to follow-up, were in NYHA Class I or II, with a mean ejection fraction of 26%, and with a demonstrated improvement in ejection fraction in every patient. A marked reduction in regurgitant volume and fraction was demonstrated. The NYHA class improved for every patient individually, and from a mean of 3.2" 0.2 to 1.8" 0.4 for the entire group. All patients reported subjective improvement in functional status. In those patients for whom preoperative data was available for comparison, peak maximal volume of O use during a 6-min walk rose signifi-2 cantly, from a mean of 14.5 to 18.6 ml O rkgrmin. The matched preoperative and 24-month postoperative echocardiographic data are recorded in Table 1 . All patients had a reduction in sphericity index and regurgitant fraction. All patients demonstrated improvement in left ventricular ejection fraction, cardiac output, and end diastolic volumes. There have been 26 late deaths in this group of patients. This number includes three patients who had further progression of disease and had undergone transplantation, and two related to complications following other operative procedures. The other deaths have resulted from pro-Ž . gression of heart failure n s 8 , despite no significant return of mitral regurgitation, sudden ventricular ar-Ž . rhythmia n s 12, 8 in ischemic patients and one suicide.
Discussion
For patients with dilated heart failure, mortality is directly related to the severity of left ventricular sysw x tolic dysfunction 19 . In addition, increased chamber sphericity and, more importantly, the presence of w x mitral insufficiency 33 are markers of a worse prognosis. In review of these types of patients, 1-year mortality has been reported between 54 and 70%. Furthermore, in a study of 28 patients awaiting transplantation, with an ejection fraction of 25% or less, 1-year survival was only 46%, and independent predictors of death were low forward-stroke volumes, a history of ventricular arrhythmia, and mitral regurgiw x tation 34 . The patients presented in our study therefore represent a group with a very high-predicted mortality.
The pathogenesis of mitral regurgitation-related myopathy is multifactorial. In the absence of organic disease, mitral regurgitation is predominantly thought to occur as a result of progressive dilation of the mitral annulus, with subsequent loss of coaptation of the valve leaflets. A large leaflet area is normally required for coaptation, because mitral leaflet area is 2.5 times greater than the area of the mitral valve orifice. As more mitral leaflet tissue is utilized for coverage of the enlarging mitral valve orifice, a critical reduction in the leaflet tissue available for coaptation is reached, and a central regurgitant jet of w x 'functional' insufficiency begins to develop 15,35 . Therefore, the most significant determinant of mitral valve coaptation, leaflet orifice area, and mitral regurgitation is the dimensions of the mitral valve annulus. The left ventricular dimension appears to be a less important factor in functional mitral regurgitation; chordal length and papillary muscle length are not significantly different in people with idiopathic heart w x failure with or without mitral regurgitation 15 .
In ischemic heart failure, the mechanisms that contribute to mitral regurgitation are complex. They may include 'functional' mitral regurgitation, through dilation of the mitral valve annulus, and 'papillary muscle dysfunction', which is an unsuccessful coordination of the entire mitral valve apparatus rather than simply w x an isolated disorder of the papillary muscle 36 . These ischemia-related changes are also thought to result in an insufficient area of coaptation of the mitral leaflets.
In a recent study of patients with severe heart failure who were managed with pharmacological Ž agents diuretics, nitrates and afterload-reducing . agents , the observed decrease in filling pressure and systemic vascular resistance led to a reduction in the dynamic mitral regurgitation associated with their heart failure. This was attributed to a reduction in the regurgitant orifice area related to the decrease in left w x ventricular volume and annular distension 37 . This complex relationship between mitral annular area and leaflet coaptation may explain why, paradoxically, an undersized 'valvular' repair can help a 'muscular' problem. Although significant undersizing of the mitral annulus was employed in our study to over-correct for the zone of coaptation, no mitral stenosis was induced, nor was any SAM of the anterior leaflet noted. SAM was avoided, due to widening of the aorto-mitral angle and increased left ventricular size seen in myopathic patients. In addition, acute remodeling of the base of the heart from the undersizing of the mitral annular ring may also contribute to the improvement seen in these myopathic hearts. This may re-establish the ellipsoid shape and somewhat normal geometry to the base of the left ventricle.
Increases in left ventricular preload, wall tension, diastolic volume, and stroke volume, are all documented ventricular adaptations to severe mitral regurgitation. Maintenance of forward flow becomes difficult, because up to 50% of the stroke volume is ejected into the left atrium, even before the aortic w x valve opens 38 . Eliminating the regurgitant volume can increase ventricular efficiency dramatically.
Successful mitral valve repair may have beneficial effects on coronary flow. One study assessed coronary flow in patients without coronary artery disease bew x fore and after mitral valve reconstruction 39 . Coronary flow reserve was limited in patients with mitral regurgitation due to an increase in basal coronary flow and flow velocity, which was related to hypertro-Ž . phy and increased preload left ventricular wall stress . The restriction in coronary flow reserve improved following mitral valve reconstruction because of a reduction in the basal coronary flow and flow velocity once the left ventricular preload, work and mass were w x reduced 39 . Based on this study, a restriction in the coronary flow reserve would seem probable in patients with mitral regurgitation and heart failure, and an improvement in flow reserve and velocity would be expected following mitral valve repair.
Heart failure is a clinical syndrome resulting from diverse and complex mechanisms. Proinflammatory Ž . cytokines, including tumor necrosis factor-␣ TNF-␣ , IL-1, IL-2 and IL-6, may not only be produced by the stressed myocardium, but also be responsible, in part, w x for myocardial depression 40᎐43 . Studies have demonstrated that this proinflammatory cytokine may play a role in the development of left ventricular dysfunction, heart failure, hypotension, and pulmow x nary edema 44᎐47 . There are two forms of TNF-␣-specific receptors: TNF-R1 and -R2. Both receptors are found in equal proportions in the normal myocardium and TNF-␣ binds with equal affinity to both receptors. The negative inotropic effects of TNF-␣ are mediated primarily by its interaction with TNF-R1. The expression of myocardial TNF-Rs is down-regulated in the presence of heart failure, similar to that w x seen with the ␤-adrenergic receptors 44,48 . The circulating, or soluble, forms of TNF-Rs are elevated in patients with heart failure, suggesting that these rew x ceptors may be 'shed' from the myocardial cells 49 . The circulating TNF-Rs can neutralize the biological w x effects of circulating TNF-␣ 50 . Based on these observations, it has been postulated that the cardiactissue response to increased TNF-␣ levels is to increase the level of soluble TNF receptors in order to decrease the amount of bioactive TNF-␣ that can w x potentially stimulate cardiac cells 44 . At the University of Michigan we have measured levels of TNF-␣, soluble TNF-R1 and -R2, IL-6 and IL-6 receptors in the pre-and post-operative period in patients undergoing mitral valve repair in the presence of heart Ž . failure Table 2 . The levels of these cytokines and their respective receptors were all decreased in these patients 6 months after mitral reconstruction. Further studies are being conducted, in which the soluble recombinant form of TNF-R is being administered to heart-failure patients in the hope of decreasing some w x of the clinical manifestations of failure 44 .
As the availability of transplantation for treatment for patients with end-stage heart failure is limited, there has been recent interest in the altered geometry of the left ventricle in patients with severe dysfunction. This innovative work was initially described by Batista, who states that all mammalian hearts share the same ratio of massrdiameter, regardless of the size of the heart. The formula that is common to all hearts should be a muscle mass that is four times the ( )Ž 3 . radius cubed Ms 4 = R . Batista proposed that those hearts that do not comply with this relationship should undergo an operative procedure to restore the w x ratio back to normal 8,9 . Surgeons have attempted to normalize this relationship by left ventricular myoreduction surgery, also called partial left ventricular reduction surgery, reduction myoplasty or the Batista procedure. Batista initially reported an operative mortality of 5%, a 30-day mortality of 22%, and a 2-year survival of 55%. Unfortunately, complete and long-term follow-up was not available for these w x patients 9,51᎐53 . This procedure has met with varying degrees of success in the United States and worldw x wide 53᎐57 . The Cleveland Clinic series of 62 Ž . patients 95% idiopathic dilated cardiomyopathy reported a 3.5% hospital mortality with seven late deaths w x and a 1-year actuarial survival of 82% 54 . All of the cases routinely had a mitral valve repair or replacement as part of the myoreduction procedure, which may have contributed to the relative success of the procedure in this center.
Mitral valve reconstruction alone also re-establishes a more normal left ventricular massrvolume w x ratio without the loss of myocardial mass 11,13 . The average left ventricular volume at 24-month follow-up in our study was over 200 ml, still quite large, while with the left ventricular myoreduction procedure, Batista has demonstrated acute reduction of LV volumes to approximately 90᎐100 ml at the time of operation. There is no loss of ventricular mass with the mitral valve reconstruction alone; however, an appropriate massrvolume ratio is restored. Importantly, there is an acceptable surgical mortality, both at 30 days and 1 year, for mitral valve reconstruction, which is equivalent to, or lower than, that reported w x for left ventricular myoreduction procedures 51᎐57 .
One must differentiate the effect of abolishing mitral regurgitation alone versus the addition of the myoreduction. In dog models, left ventricular remodeling may be rapid and complete, with resultant regurgitant fractions of less than 30% after correction w x of the mitral regurgitation alone 58 . In the University of Michigan study, a decrease in sphericity index and left ventricular volume measurements were demonstrated post-operatively, and it is in these patients that the negative cycle of heart failure is interrupted and the surgical unloading of the left ventricle is achieved. These patients may be undergoing slow reverse remodeling due to the alteration of the angulation of the base of the heart, stabilization of the mitral annulus, or left ventricular unloading. Beneficial remodeling tends to occur more frequently in the patients with idiopathic, as opposed to those with ischemic, heart failure. In the hearts with end-stage ischemic heart failure the potential for remodeling may be limited, due to presence of scar in the ventricular wall.
Conclusion
In conclusion, mitral reconstruction via an annuloplasty ring effectively corrects mitral regurgitation in heart-failure patients and is a relatively safe procedure in a high-risk population. Not only does it appear to improve survival, but also functional status, often remarkably. While longer-term follow-up is necessary with a greater number of patients, we are encouraged by these results, and feel that mitral reconstruction offers a new strategy for end-stage heart failure. 
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